Ceryvyn Therapeutics Limited, formerly Opthea Limited, is an Australia-based clinical-stage biopharmaceutical company. The Company is focusing on developing therapies by translating advances in human biology into transformative medicines for patients with serious diseases. It focuses on identifying biological mechanisms that drive disease and developing targeted therapies capable of addressing unmet medical needs. Its focus is lymphangioleiomyomatosis (LAM), a rare, chronic and progressive systemic disease that predominantly affects women and primarily involves the lungs, where it leads to progressive loss of lung function. The Company's lead development program, CYV-101, is a fusion protein designed to selectively bind and neutralize VEGF-C and VEGF-D, key signaling proteins involved in pathological lymphangiogenesis. It targets a fundamental biological pathway to drive disease progression, CYV-101 offers a differentiated therapeutic approach for patients with LAM.
Back to dashboard
Company Information
About this company
Key people
Jeremy Max Levin
Non-Executive Independent Chairman of the Board
Megan Baldwin
Founder, Chief Innovation Office
Hamish George
Chief Financial Officer, Joint Company Secretary
Karen Adams
Vice President - Finance
Stephanie Vipond
Joint Company Secretary
Katherine Connell
Non-Executive Independent Director
Lawrence Gozlan
Non-Executive Independent Director
Click to see more
Key facts
- Shares in issue1.37bn
- EPICCYVNY
- ISINUS68386J2087
- LocationAustralia
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$11.49m
- Employees-
- ExchangeOver The Counter
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.